Boehringer Ingelheim Presents Positive Results From Phase I Tumor Study
Posted on: Thursday, 23 October 2008, 09:00 CDT
Boehringer Ingelheim has announced that its new cell cycle kinase inhibitor and potentially first-in-class compound, BI 6727, has shown encouraging results in a Phase I clinical trial in patients with advanced tumors who have failed to respond to other treatments.
In the study, which assessed the maximum tolerated dose, overall safety, pharmacokinetics and preliminary efficacy of BI 6727, a total of 50 patients were treated at doses of 12 to 450mg. Results were encouraging; 32% of patients had stable disease and two patients with advanced bladder and ovarian cancers showed confirmed responses, both of whom had previously failed other standard and experimental treatments, the company said.
According to the company, the clear antitumor activity demonstrated, not typically seen in a Phase I trial, illustrates the significance of these findings. Furthermore, BI 6727 was shown to be well-tolerated with no serious side effects detected.
Preclinical data also showed highly selective target inhibition, cellular activity at very low levels and long-lasting tumor exposure for BI 6727. This, combined with the Phase I data presented suggests a promising future for BI 6727, supporting Plk1 as a therapeutic target and warranting further investigation, said Boehringer Ingelheim.
Based on the encouraging results, BI 6727 will advance further in clinical development. The Phase II program will assess the efficacy and safety of BI 6727 in several tumor types.
Manfred Haehl, corporate senior vice president of medicine at Boehringer Ingelheim, said: "The latest data for our Plk1 inhibitor BI 6727, including initial safety and efficacy results, further reinforce our continued growth in oncology research and are evidence of our sustained leadership in Plk1 inhibition. As a company, we are really excited by the potential these impressive first results hold and look forward to ongoing growth within our oncology pipeline."
Source: Datamonitor
Related Articles
- Afinitor(R) Phase II Data Show Positive Results for Patients With Multiple Types of Lymphoma, Leading to Phase III Trial
- CuraGen Reports Encouraging Preliminary Data From Phase II Melanoma Trial
- Medgenics Announces Encouraging Preliminary Data for Phase I/II Clinical Trial of EPODURE in Renal Anemia
- Ariad Reports Encouraging Preclinical Data From Prostate Cancer Study
- Javelin Enrolls First Patient in an Open Label Safety Study of Dyloject(TM)
- IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
- Incyte Cites Encouraging Clinical Data in Multiple Programs; Announces Second Quarter 2007 Financial Results
- ArQule Announces Encouraging Interim Data From Phase 1 Trial With C-Met Inhibitor, ARQ 197
- Alexion Pharmaceuticals Reports Positive Phase III Results for Eculizumab From Pivotal TRIUMPH Efficacy Trial in Paroxysmal Nocturnal Hemoglobinuria Patients
- Data and Safety Monitoring Board Recommends Discontinuation of Canvaxin(TM) Phase 3 Clinical Trial for Patients With Stage III Melanoma
 |
 |
User Comments (0)
RSS Feeds